POAI - Earnings call transcript Q1 2019 | Predictive Oncology Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Precision Therapeutics Earnings Conference Call for the First Quarter Ended March 31, 2019. All participants will be in a listen-only mode. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A replay of the call will be available approximately one hour after the end of the call through June 15, 2019. I would now like to turn the conference call over to Scott Gordon, President of CORE IR, the company's investor relations firm. sir. ahead, go Please

Scott Gordon

Officer; With and discuss all and Precision Chief XXXX. first Eastern XX, Chief first for P.M. Bob Myers, today, Jamie, Dr. quarter conference for the Precision financial joining call the XXXX. March ended to Therapeutics Therapeutics quarter ended Carl Financial Executive today the thank At you, are for you today's XX, Officer. results Schwartz, and company's us results March Thank X:XX corporate Time company's released developments financial

have not the you received If release, Precision please Investors Therapeutics' visit www.precisiontherapeutics.com. earnings page at

course the not statements This regarding new markets, projections statements conditions statements assumptions that risks other of from management objectives forward-looking forward-looking that or uncertainties regarding the the this the results. proposed materially making conference of international of new products services, regarding in services and this the the is plans, date of the statement cause call the to on of subject company's statements statements. During cautions products any as any any expectations underlying statement based concerning to includes in are of to assumptions agreements, any of described any are about and of statements U.S. numerous and expectations actual relating those fact conference and statements anticipated statement. differ future future a could or success Any and relationships company results economic statements or belief or statements financial or will the of you performance, company's and for any statements These forward-looking any revenues, company strategies The call, earnings, of for operations, be future is cash that historical statements. a any foregoing.

reflect Therapeutics Exchange Therapeutics. are with on assumes to periodic or no Commission. my Cautionary Precision in and in the company obligation outcomes actual the Some reports to the Dr. do files release to statements of does risks. risks of forward-looking read Schwartz? over Precision investors pleasure potential intend is of public today's to should call Note press Securities these these section update and Investors and or forward-looking CEO Schwartz, described titled It Dr. Carl now so. future events statements turn the to these not the

Carl Schwartz

employing human the as cancer advanced in and cutting-edge of they Precision. These Welcome methods We and excellence now of at cells body. the begun treatment. completion for merger, quarters. mechanism pleased precision results of responding a the still I'm wholly-owned Precision development forefront today's the and discuss we TumorGenesis, quarter-ended call developments for which into the to our you the thank some focus flight. treatments in we and the our the the stand that subsidiary, in for for advancement joining XXXX Helomics in coming were person's medicine of drugs in to Therapeutics report the that artificial propensity mission accomplishments to the With is personalized in to financial of position full treatments medicine company analytics, corporate fool the is targeting genetic Precision cancers become are intelligence use our a March of have to XX, The respond individualized advancing notable with if at the for are tools specific and conference XXXX. to

can strong some. accomplishing are going and we're work that alliances learn we with important we about partners creating While our goals, with

and gain have technological our in positions We quarter intellectual bears and that first Helomics to monetize opportunity property much fruit superiority. the accomplished our merger from to us

ovarian cancer. these Viome determine gut to and announced role microbiome of of Some a are between Helomics in examples our collaboration

Helomics. service next $XXX,XXX partner agreement development Alberta XXHour a We also Artificial grant drug trial. generation SpeciCare precision announce Alopecia research. Foundation to and registry for three the in provide for patient announced an We services and And were thrilled Intelligence Helomics to Innovates and received the with for thyroid types for Areata its a partnership Areata and novel provide CRO Discovery development have Helomics of SpeciCare signing National TumorGenesis biomarkers. will to discovery cancer has TumorGenesis treatments isolated Alopecia cancer identified medicine announced

distribution the agreement Therapeutics' we sale of the Saudi further by division Arabian the units widened expanding Scientific. reach And four a new Skyline Skyline Precision Medical its Medical entered African with through global front, STREAMWAY On continent, global through our distributor. the Winner company's presence Taiwanese

the their look excited truly look device we're We for we the in government evolving And waste and - their of prospects they medical excited the and solution landscape use of have as placed health those adoption hospitals that of our clinics global where developments disposal. regulations in STREAMWAY are reporting forward on to encourage As developments advanced about have as ahead a about coming viable the further used India, quarters, qualifications authorities a expansion. its could occur. system addressing and to to in we

who our a additional leader precision we the Bob? with medicine the the pipeline turn as call for in to will results have questions. our developments Myers, of over thoughts I will number the be space. our call weeks And an the closing Bob quarters reporting emerging open some then will CFO, quarter. discuss further in that that also and exciting and financial will position With coming that, will in the to I strengthen on We return

Bob Myers

results a Revenue, for revenue of XXXX quarter first discuss quarter the XX% for XXXX. Thank first This XX, for our you, with was Carl, $XXX,XXX $XXX,XXX compared and the represents I year-over-year. XXXX. now welcome, ended March the everyone. decrease financial will

the in the The increased the improve through expenses expenses legal to merger of which to March comparable $XXX,XXX sales, and X ended by of the disposable in comparable in to consisted our increase three XXXX discounts in same in and and in expenditure to quarter next of units STREAMWAY months over margins. virtually was three the Our Cost period. turn the solutions, cost revenue the the were to March increased to expense, three March XX, General sales expect We compared $XXX,XXX March we and STREAMWAY accounting ended three sales year. compared of XX, producing ended period. XXXX the in XXXX. sales XX, XX, and internationally $XX,XXX in Operating months months ended months three allow of units, due ended and compared equipment XXXX months There of the both approximately prior XX, in March Eventually, X the XX, research to $XXX,XXX STREAMWAY XXXX audit the March XX, we increased sales volume administrative included increases sale expect were X March by $XXX,XXX ended, gross were achieve months our sales significant the the X supplies. three the and purchasing. We'll March was fees. ended XX XXXX STREAMWAY months expenses months domestically our us and ended XX% get in sheet. systems three relevant cleaning development, The to to XXXX. expenses generation operating XX% our profit marketing And largest XXXX. for our most compared same XX, The three and on to XXXX margin our components our balance system.

February note As XXXX, million] invest approximately million. Helomics and of $X.X total XX, XXXX, the it merger XXXX, closed business. loan offerings, [in the back March With that, receiving financing was of company the to cash in Please medicine equivalents XXXX balance I company's to turn precision balance March Schwartz. investment expects will $X.X support of equaling cash $X.X two require from January closed was Schwartz. In and company The the Dr. $XXX,XXX. Dr. Carl? XX, our X million. received on approximately on that cash additional need will company the CEO, public the call additional that a net an April to Carl [ph] our the At on and

Carl Schwartz

Thanks, Bob.

continued - about bringing truly medicine team, cancer get than and patients by to our excited hope a tools more work these transformation to of is into job are provider discovery drug cutting-edge ever. a much our hard forward dedicated a team We dedicated innovations. After solutions personalized totally

systems, pleased with are We domestically and can about and STREAMWAY any We [ph] distribution both progress internationally. be believe our this product the facility issues] of handling on to the marketing just infectious wastes. [that benefit a

a as have we strong We on executed of to already are in business successes. variety off start XXXX a

questions. continued consistent continued I expect wish us support. will let's loyal dependable We shareholders begin call reliable up the create for for thank our to that and efforts open to their value. long-term enable our delivery to Operator, will performance

Operator

Instructions] this allotted at to minutes from back analysts. remarks. Dr. conference At equity Schwartz Ladies turn time, gentlemen, over like our call have address I'd conclude this we we closing will to time, to and the question-and-answer XX for questions session. [Operator

Carl Schwartz

Thank wish to you, for time your again everyone thank operator. today. I

the Thank and continued for you, Therapeutics excited represents your value on that focus achieving delivering support. are promise the We shareholders. to and about lasting loyal future Precision and for time our you our again

to coming continuing in achievements months. our on to the report forward look will We

Operator

The presentation. conference today's is attending concluded. for you We now thank do

disconnect may now You your lines.

Predictive Oncology (POAI) 15 May 192019 Q1 Earnings call transcript